These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 28183563)

  • 1. Effect of basal insulin dosage on blood glucose concentration in ambulatory surgery patients with type 2 diabetes.
    Demma LJ; Carlson KT; Duggan EW; Morrow JG; Umpierrez G
    J Clin Anesth; 2017 Feb; 36():184-188. PubMed ID: 28183563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin glargine dosing before next-day surgery: comparing three strategies.
    Rosenblatt SI; Dukatz T; Jahn R; Ramsdell C; Sakharova A; Henry M; Arndt-Mutz M; Miller V; Rogers K; Balasubramaniam M
    J Clin Anesth; 2012 Dec; 24(8):610-7. PubMed ID: 23122972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glargine Insulin Use Versus Continuous Regular Insulin in Diabetic Surgical Noncritically Ill Patients Receiving Parenteral Nutrition: Randomized Controlled Study.
    Hakeam HA; Mulia HA; Azzam A; Amin T
    JPEN J Parenter Enteral Nutr; 2017 Sep; 41(7):1110-1118. PubMed ID: 27091835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in inpatient glycemic control and response to subcutaneous insulin therapy between medicine and surgery patients with type 2 diabetes.
    Smiley D; Umpierrez GE; Hermayer K; Newton C; Jacobs S; Olson DE; Khan A; Rizzo M; Peng L; Reyes D; Cardona S; Fonseca V
    J Diabetes Complications; 2013; 27(6):637-41. PubMed ID: 23911535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the Efficacy and Safety of Insulin Detemir and Insulin Glargine in Hospitalized Patients with Type 2 Diabetes: A Randomized Crossover Trial.
    Zhang T; Lin M; Li W; Fan X; Du T; Zhao Y; Zhang X
    Adv Ther; 2016 Feb; 33(2):178-85. PubMed ID: 26809253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8.
    Harris C; Forst T; Heise T; Plum-Mörschel L; Watkins E; Zhang Q; Fan L; Garhyan P; Porksen N
    Diabetes Technol Ther; 2017 Aug; 19(8):463-470. PubMed ID: 28817342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized Controlled Trial Comparing Glargine U300 and Glargine U100 for the Inpatient Management of Medicine and Surgery Patients With Type 2 Diabetes: Glargine U300 Hospital Trial.
    Pasquel FJ; Lansang MC; Khowaja A; Urrutia MA; Cardona S; Albury B; Galindo RJ; Fayfman M; Davis G; Migdal A; Vellanki P; Peng L; Umpierrez GE
    Diabetes Care; 2020 Jun; 43(6):1242-1248. PubMed ID: 32273271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of weight-based insulin glargine dose titration regimen compared with glucose level- and current dose-based regimens in hospitalized patients with type 2 diabetes: a randomized, controlled study.
    Li X; Du T; Li W; Zhang T; Liu H; Xiong Y
    Clin Ther; 2014 Sep; 36(9):1269-75. PubMed ID: 25062651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of prandial treatment timing adjustment, based on continuous glucose monitoring, in patients with type 2 diabetes uncontrolled with once-daily basal insulin: A randomized, phase IV study.
    Ilany J; Bhandari H; Nabriski D; Toledano Y; Konvalina N; Cohen O
    Diabetes Obes Metab; 2018 May; 20(5):1186-1192. PubMed ID: 29316176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of tofogliflozin 20 mg and ipragliflozin 50 mg used together with insulin glargine 300 U/mL using continuous glucose monitoring (CGM): A randomized crossover study.
    Takeishi S; Tsuboi H; Takekoshi S
    Endocr J; 2017 Oct; 64(10):995-1005. PubMed ID: 28824042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of once-daily glargine insulin with twice-daily NPH/regular insulin for control of hyperglycemia in inpatients after cardiovascular surgery.
    Yeldandi RR; Lurie A; Baldwin D
    Diabetes Technol Ther; 2006 Dec; 8(6):609-16. PubMed ID: 17109592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine.
    Garg SK; Gottlieb PA; Hisatomi ME; D'Souza A; Walker AJ; Izuora KE; Chase HP
    Diabetes Res Clin Pract; 2004 Oct; 66(1):49-56. PubMed ID: 15364161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial.
    Bolli GB; Riddle MC; Bergenstal RM; Wardecki M; Goyeau H; Home PD;
    Diabetes Metab; 2017 Sep; 43(4):351-358. PubMed ID: 28622950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes.
    Riddle MC; Bolli GB; Home PD; Bergenstal RM; Ziemen M; Muehlen-Bartmer I; Wardecki M; Vinet L; Jeandidier N; Yki-Järvinen H
    Diabetes Technol Ther; 2016 Apr; 18(4):252-7. PubMed ID: 26840338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liberating A1C goals in older adults may not protect against the risk of hypoglycemia.
    Munshi MN; Slyne C; Segal AR; Saul N; Lyons C; Weinger K
    J Diabetes Complications; 2017 Jul; 31(7):1197-1199. PubMed ID: 28343792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Telephone-Delivered Interventions on Glycemic Control in Type 2 Diabetes Treated with Glargine Insulin.
    Bellido V; Bellido D; Tejera C; Carral F; Goicolea I; Soto A; García Almeida JM; Morales C; López de la Torre M
    Telemed J E Health; 2019 Jun; 25(6):471-476. PubMed ID: 30036160
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance Measures.
    Lingvay I; Chao J; Dalal MR; Meneghini LF
    Diabetes Technol Ther; 2017 May; 19(5):315-322. PubMed ID: 28467113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosing of insulin glargine in the treatment of type 2 diabetes.
    Barnett A
    Clin Ther; 2007 Jun; 29(6):987-99. PubMed ID: 17692716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Algorithm that delivers an individualized rapid-acting insulin dose after morning resistance exercise counters post-exercise hyperglycaemia in people with Type 1 diabetes.
    Turner D; Luzio S; Gray BJ; Bain SC; Hanley S; Richards A; Rhydderch DC; Martin R; Campbell MD; Kilduff LP; West DJ; Bracken RM
    Diabet Med; 2016 Apr; 33(4):506-10. PubMed ID: 26220149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin Glargine in Critically ill Patients: Once/Day versus Twice/Day Dosing.
    Fox MA; Perry MC; Liu-DeRyke X
    Pharmacotherapy; 2020 Mar; 40(3):186-190. PubMed ID: 31995840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.